Soleno Therapeutics Inc’s (NASDAQ:SLNO) Earnings Dropped -120.49%, Did Its Industry Show Weakness Too?

Assessing Soleno Therapeutics Inc’s (NASDAQ:SLNO) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, which is a great indicator for future performance. Below, I assess SLNO’s latest performance announced on 30 September 2017 and evaluate these figures to its historical trend and industry movements. View our latest analysis for Soleno Therapeutics

How Well Did SLNO Perform?

To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. This enables me to examine many different companies on a similar basis, using the most relevant data points. For Soleno Therapeutics, its most recent trailing-twelve-month earnings is -$18.0M, which, in comparison to last year’s figure, has become more negative. Given that these values are relatively short-term thinking, I’ve computed an annualized five-year value for SLNO’s earnings, which stands at -$12.6M. This doesn’t seem to paint a better picture, since earnings seem to have gradually been getting more and more negative over time.

NasdaqCM:SLNO Income Statement Jan 5th 18
NasdaqCM:SLNO Income Statement Jan 5th 18
We can further analyze Soleno Therapeutics’s loss by researching what’s going on in the industry as well as within the company. First, I want to briefly look into the line items. Revenue growth over the last few years has risen by 19.46%, signalling that Soleno Therapeutics is in a high-growth phase with expenses racing ahead elevated top-line growth rates, leading to yearly losses. Scanning growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% in the past twelve months, and 20.18% over the past five. This shows that any uplift the industry is deriving benefit from, Soleno Therapeutics has not been able to realize the gains unlike its industry peers.

What does this mean?

Though Soleno Therapeutics’s past data is helpful, it is only one aspect of my investment thesis. With companies that are currently loss-making, it is always difficult to predict what will happen in the future and when. The most useful step is to assess company-specific issues Soleno Therapeutics may be facing and whether management guidance has dependably been met in the past. I suggest you continue to research Soleno Therapeutics to get a more holistic view of the stock by looking at:

1. Future Outlook: What are well-informed industry analysts predicting for SLNO’s future growth? Take a look at our free research report of analyst consensus for SLNO’s outlook.

2. Financial Health: Is SLNO’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.

3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the trailing twelve months from 30 September 2017. This may not be consistent with full year annual report figures.